{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:19:02Z","timestamp":1787933942032,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010875","name":"Amgen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40119-024-00349-6","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T15:03:11Z","timestamp":1706540591000},"page":"205-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9736-6970","authenticated-orcid":false,"given":"Erin S.","family":"Mackinnon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1040-6229","authenticated-orcid":false,"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2422-7758","authenticated-orcid":false,"given":"Rajvi J.","family":"Wani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7319-4369","authenticated-orcid":false,"given":"Natasha","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6537-1898","authenticated-orcid":false,"given":"Eileen","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0960-0761","authenticated-orcid":false,"given":"Kelcie","family":"Witges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-2440","authenticated-orcid":false,"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"issue":"11","key":"349_CR1","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/clc.23732","volume":"44","author":"G Chen","year":"2021","unstructured":"Chen G, Farris MS, Cowling T, et al. Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: a real-world evidence study. Clin Cardiol. 2021;44(11):1613\u201320.","journal-title":"Clin Cardiol"},{"issue":"3","key":"349_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.cjca.2016.11.009","volume":"33","author":"JV Tu","year":"2017","unstructured":"Tu JV, Khan AM, Ng K, Chu A. Recent temporal changes in atherosclerotic cardiovascular diseases in Ontario: clinical and health systems impact. Can J Cardiol. 2017;33(3):378\u201384.","journal-title":"Can J Cardiol"},{"issue":"8","key":"349_CR3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","volume":"37","author":"GJ Pearson","year":"2021","unstructured":"Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129\u201350.","journal-title":"Can J Cardiol"},{"issue":"18","key":"349_CR4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"349_CR5","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"8","key":"349_CR6","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamacardio.2020.0882","volume":"5","author":"B Gencer","year":"2020","unstructured":"Gencer B, Mach F, Murphy SA, et al. Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial. JAMA Cardiol. 2020;5(8):952\u20137.","journal-title":"JAMA Cardiol"},{"issue":"12","key":"349_CR7","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"349_CR8","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","volume":"138","author":"MS Sabatine","year":"2018","unstructured":"Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER. Circulation. 2018;138(8):756\u201366.","journal-title":"Circulation"},{"issue":"8","key":"349_CR9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","volume":"7","author":"KK Ray","year":"2019","unstructured":"Ray KK, Colhoun HM, Szarek M, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):618\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"349_CR10","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jacc.2019.07.015","volume":"74","author":"SG Goodman","year":"2019","unstructured":"Goodman SG, Aylward PE, Szarek M, et al. Effects of alirocumab on cardiovascular events after coronary bypass surgery. J Am Coll Cardiol. 2019;74(9):1177\u201386.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"349_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/ehjqcco\/qcy058","volume":"5","author":"M Lindh","year":"2019","unstructured":"Lindh M, Banefelt J, Fox KM, et al. Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data. Eur Heart J Qual Care Clin Outcomes. 2019;5(3):225\u201332.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"12","key":"349_CR12","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.jacc.2020.07.033","volume":"76","author":"M Sud","year":"2020","unstructured":"Sud M, Han L, Koh M, et al. Low-density lipoprotein cholesterol and adverse cardiovascular events after percutaneous coronary intervention. J Am Coll Cardiol. 2020;76(12):1440\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"349_CR13","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1161\/01.STR.0000174293.17959.a1","volume":"36","author":"RA Kokotailo","year":"2005","unstructured":"Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using International Classification of Diseases, revisions 9 and 10. Stroke. 2005;36(8):1776\u201381.","journal-title":"Stroke"},{"issue":"11","key":"349_CR14","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","volume":"32","author":"TJ Anderson","year":"2016","unstructured":"Anderson TJ, Gr\u00e9goire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32(11):1263\u201382.","journal-title":"Can J Cardiol"},{"issue":"2","key":"349_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","volume":"29","author":"TJ Anderson","year":"2013","unstructured":"Anderson TJ, Gr\u00e9goire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2):151\u201367.","journal-title":"Can J Cardiol"},{"issue":"10","key":"349_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0828-282X(09)70715-9","volume":"25","author":"J Genest","year":"2009","unstructured":"Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society\/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009;25(10):567\u201379.","journal-title":"Can J Cardiol"},{"issue":"32","key":"349_CR17","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"25","key":"349_CR18","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"issue":"1","key":"349_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"9753","key":"349_CR20","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"25","key":"349_CR21","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"7","key":"349_CR22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamacardio.2019.0886","volume":"4","author":"SA Murphy","year":"2019","unstructured":"Murphy SA, Pedersen TR, Gaciong ZA, et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial. JAMA Cardiol. 2019;4(7):613\u20139.","journal-title":"JAMA Cardiol"},{"issue":"5","key":"349_CR23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","volume":"168","author":"GG Schwartz","year":"2014","unstructured":"Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682\u20139.","journal-title":"Am Heart J"},{"issue":"10106","key":"349_CR24","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962\u201371.","journal-title":"Lancet"},{"issue":"16","key":"349_CR25","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","volume":"147","author":"P Gaba","year":"2023","unstructured":"Gaba P, O\u2019Donoghue ML, Park JG, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE. Circulation. 2023;147(16):1192\u2013203.","journal-title":"Circulation"},{"issue":"4","key":"349_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.006646","volume":"14","author":"B Sarak","year":"2021","unstructured":"Sarak B, Savu A, Kaul P, et al. Lipid testing, lipid-modifying therapy, and PCSK9 (proprotein convertase subtilisin-kexin type\u00a09) inhibitor eligibility in 27 979 patients with incident acute coronary syndrome. Circ Cardiovasc Qual Outcomes. 2021;14(4):e006646.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"349_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40119-022-00300-7","volume":"12","author":"ES Mackinnon","year":"2023","unstructured":"Mackinnon ES, Har B, Champsi S, et al. Guideline LDL-C threshold achievement in acute myocardial infarction patients: a real-world evidence study demonstrating the impact of treatment intensification with PCSK9i. Cardiol Ther. 2023;12:327\u201338.","journal-title":"Cardiol Ther"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-024-00349-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T19:07:05Z","timestamp":1709060825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-024-00349-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["349"],"URL":"https:\/\/doi.org\/10.1007\/s40119-024-00349-6","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"assertion":[{"value":"20 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Amgen Canada Inc. (Amgen). Erin S. Mackinnon, Rajvi J. Wani, and Natasha Burke are employed by Amgen, who funded this study and hold Amgen stock. Lawrence A. Leiter has received research support from, has provided CME on behalf of and\/or has acted as an advisor to Amarin, Amgen, AstraZeneca, Esperion, HLS, Kowa, Merck, Novartis, Pfizer, and Sanofi. Eileen Shaw and Kelcie Witges are employed by Medlior Health Outcomes Research Ltd., which received funding for the study from Amgen. Shaun G. Goodman reports research grant support (e.g., steering committee or data and safety monitoring committee) and\/or speaker\/consulting honoraria (e.g., advisory boards) from: Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, CYTE Ltd., Daiichi-Sankyo\/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, Novo Nordisk A\/C, Pendopharm\/Pharmascience, Pfizer, Regeneron, Sanofi, Servier, Tolmar Pharmaceuticals, Valeo Pharma; and salary support\/honoraria from the Heart and Stroke Foundation of Ontario\/University of Toronto (Polo) Chair, Canadian Heart Failure Society, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, PERFUSE Research Institute, TIMI Study Group (Brigham Health).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study complies with the Declaration of Helsinki and was approved by the Health Research Ethics Board of Alberta\u2013Community Health Committee (HREBA-CHC). Patient consent for participation was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}